Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deena Kuruvilla

Neurology Westport, CT Medical Doctor

NPI 1588975429 CMS profile 298612

1 Turkey Hill Rd S Ste 201, Westport, CT 06880

Open in the dashboard

General payments

$439,848

610 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deena Kuruvilla of Westport, CT is reported in the CMS Open Payments database as having received $439,848 across 610 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $54,026 45
2024 General $49,315 48
2023 General $31,060 56
2022 General $112,266 110
2021 General $79,022 95
2020 General $59,584 128
2019 General $54,576 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deena Kuruvilla
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Deena Kuruvilla were reported at $54,026. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Deena Kuruvilla Neurology median Middle half National median
2019 $54,576 $474 $118–$2,177 $163
2020 $59,584 $367 $82–$2,309 $114
2021 $79,022 $438 $104–$2,547 $132
2022 $112,266 $442 $103–$2,388 $149
2023 $31,060 $464 $119–$2,312 $160
2024 $49,315 $468 $119–$2,323 $164
2025 $54,026 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $203,602 307 payments
  2. AbbVie, Inc. $163,413 166 payments
  3. Pfizer Inc. $25,256 29 payments
  4. Allergan Inc. $24,190 39 payments
  5. Amgen Inc. $19,860 31 payments
  6. Biohaven Pharmaceuticals, Inc. $2,467 9 payments
  7. Lundbeck LLC $330 8 payments
  8. Teva Pharmaceuticals USA, Inc. $228 9 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $186 4 payments
  10. Impel Pharmaceuticals Inc. $98 1 payment
  11. Other $219 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $315,979 181 payments
  2. Consulting Fee $75,435 32 payments
  3. Travel and Lodging $36,751 100 payments
  4. Food and Beverage $11,428 292 payments
  5. Education $168 3 payments
  6. Grant $88 2 payments
Products named General payments · program years 2019–2025
  1. REYVOW $102,471 106 payments
  2. EMGALITY $94,377 128 payments
  3. UBRELVY Neuroscience $81,579 78 payments
  4. QULIPTA $66,867 74 payments
  5. AIMOVIG $17,335 29 payments
  6. UBRELVY Neuroscience $15,698 33 payments
  7. NURTEC ODT Pain $13,384 24 payments
  8. BOTOX $6,300 1 payment
  9. ZAVZPRET $3,906 13 payments
  10. NURTEC ODT Primary Care $2,653 13 payments
  11. Other $3,789 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

41

Median for Neurology: 833

Drug cost

$79,762

Median for Neurology: $202,670

Branded share of claims

58.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 11 $44,790
Qulipta Atogepant Brand 13 $34,341
Tizanidine Hcl Generic 17 $631

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$8,260 11 —
NURTEC ODT
$8,042 — —
QULIPTA
$2,684 13 —
ZAVZPRET
$1,878 — —
VYEPTI
$247 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

610 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record